Recombinant Anti-CD15 x Anti-CD64 Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-CD15 antibody variable domain is fused to the C terminal of an IgG of anti-CD64 antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can retarget neutrophils to tumor cells. It is designed for the research of Leukemia therapy.